Enantioselective local disposition of semotiadil (R-enantiomer) and levosemotiadil (S-enantiomer) in perfused rat liver

Drug Metabolism and Disposition

Volumn 25, Issue 3, 1997, Pages 281-286

  Ueda, Kenji ^b   Yamaoka, Kiyoshi ^a   Rodriguez, Maria Esther ^b   Shibukawa, Akimasa ^b   Nakagawa, Terumichi ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; LEVOSEMOTIADIL; SESAMODIL FUMARATE; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CALCIUM ANTAGONISM; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG DISPOSITION; DRUG LIVER LEVEL; DRUG METABOLISM; ENANTIOMER; HEART ARRHYTHMIA; HYPERTENSION; LIVER PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY;

ANIMALS; CALCIUM CHANNEL BLOCKERS; EVANS BLUE; LIVER; MALE; PERFUSION; RATS; RATS, WISTAR; SERUM ALBUMIN, BOVINE; STEREOISOMERISM; THIAZOLES;

ANGINA; ANIMALIA; BOVINAE;

EID: 0030893259     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. 2+ channel antagonist, on the electrical activity of Langendorff-perfused guinea pig hearts in comparison with diltiazem, amlodipine and nifedipine. Eur. J. Pharmacol. 286, 71-78 (1995).
2. 2+ level and force of contraction in porcine coronary arteries. Br. J. Pharmacol. 114, 1289-1295 (1995).
3. 2+ antagonist, in isolated guinea pig and rabbit hearts. J. Cardiovasc. Pharmacol. 16, 769-775 (1990).
4. N. Teramoto: Mechanisms of the inhibitory action of semotiadil fumarate, a novel Ca antagonist, on the voltage-dependent Ca current in smooth muscle cells of the rabbit portal vein. Jpn. J. Pharmacol. 61, 183-195 (1993).
5. K. Nishimura, N. Miyawaki, H. Yamauchi, and T. Iso: Tissue selectivity of the novel calcium antagonist sesamodil fumarate in isolated smooth muscles and cardiac muscles. Arzneimittelforschung 40, 244-248 (1990).
6. M. Kageyama, K. Nishimura, T. Takada, N. Miyawaki, and H. Yamauchi: SD-3211, a novel benzothiazine calcium antagonist, alone and in combination with a beta-adrenoceptor antagonist, produces antihypertensive effects without affecting heart rate and atrioventricular conduction in conscious renal hypertensive dogs. J. Cardiovasc. Pharmacol. 17, 102-107 (1991).
7. T. Takada, N. Miyawaki, M. Kageyama, K. Matsuno, N. Ishida, H. Yamauchi, and T. Iso: Antihypertensive effect of a novel calcium antagonist, SD-3211, in experimental hypertensive rats. J. Cardiovasc. Pharmacol. 18, 855-862 (1991).
8. ++ antagonist, on vasopressin induced ST segment depression in rats. Jpn. J. Pharmacol. 55 (Suppl. I), 328p (1991).
9. ++ antagonist, SD-3211 (semotiadil) in rats. Jpn. J. Pharmacol. 52 (Suppl. I), 203p (1990).
10. I. Kodama, R. Suzuki, K. Maruyama, and J. Toyama: Electrophysiological effects of SD-3212, a new antiarrhythmic agent with vasodilator action, on guinea-pig ventricular cells. Br. J. Pharmacol. 114, 503-509 (1995).
11. K. Nakayama, K. Morimoto, Y. Nozawa, and Y. Tanaka: Calcium antagonistic and binding properties of semotiadil (SD-3211), a benzothiazine derivative assessed in cerebral and coronary arteries. J. Cardiovasc. Pharmacol. 20, 380-391 (1992).
12. ++ channel blocker, SD-3212: a comparison with its enantiomer (SD-3211). Drug Dev. Res. 22, 293-298 (1991).
13. ++ channel blocker, in anaesthetized dogs with myocardial infarction in comparison with its stereoisomer (SD-3211) and bepridil. Naunyn-Schmiedeberg's Arch. Pharmacol. 345, 688-695 (1992).
14. A. Hirasawa, A. Haruno, T. Matsuzaki, and K. Hashimoto: Effects of a new antiarrhythmic drug, SD-3212, on canine ventricular arrhythmia models. Jpn. Heart J. 33, 851-861 (1992).
15. M. Fukuchi, T. Uematsu, S. Nagashima, and M. Nakashima: Antiarrhythmic effects of a benzothiazine derivative (SD-3211) and its stereoisomer (SA3212) in anaesthetized rats and isolated perfused rat hearts compared with bepridil. Naunyn-Schmiedeberg's Arch. Pharmacol. 341, 557-564 (1990).
16. Y. Hara and H. Nakaya: SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells. Br. J. Pharmacol. 116, 2750-2756 (1995).
17. N. Morikawa, H. Takashina, H. Ibuki, H. Matsuoka, H. Yamaguchi, S. Miyagi, and M. Horiuchi: Studies on the metabolic fate of semotiadil fumarate (SD-3211) (I): absorption, distribution, metabolism and excretion after single administration to male rats. Xenobiot. Metab. Dispos. 7, 315-330 (1992).
18. K. Yamaoka and T. Nakagawa: Moment analysis for reaction chromatography. J. Chromatogr. 117, 1-10 (1976).
19. O. Levenspiel: Nonideal flow: dispersion model (dispersed plug flow). In "Chemical Reaction Engineering," 2nd ed., pp. 272-290. John Wiley & Sons, New York, 1972.
20. M. S. Roberts and M. Rowland: Hepatic elimination - dispersion model. J. Pharm. Sci. 74, 585-587 (1985).
21. M. S. Roberts and M. Rowland: A dispersion model of hepatic elimination. 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. 14, 227-260 (1986).
22. Y. Yano, K. Yamaoka, Y. Aoyama, and H. Tanaka: Two-compartment dispersion model for analysis of organ perfusion system of drugs by fast inverse Laplace transform (FILT). J. Pharmacokinet. Biopharm. 17, 179-202 (1989).
23. Y. Yano, K. Yamaoka, T. Minamide, T. Nakagawa, and H. Tanaka: Evaluation of protein binding effect on local disposition of oxacillin in rat liver by a two-compartment dispersion model. J. Pharm. Pharmacol. 42, 632-636 (1990).
24. Y. Yano, K. Yamaoka, H. Yasui, and T. Nakagawa: Effect of perfusion rate on the local disposition of cefixime in liver perfusion system based on two-compartment dispersion model. Drug Metab. Dispos. 19, 1022-1027 (1991).
25. A. M. Evans, Z. Hussein, and M. Rowland: A two-compartment dispersion model describes the hepatic outflow profile of diclofenac in the presence of its binding protein. J. Pharm. Pharmacol. 43, 709-714 (1991).
26. J. M. Diaz-Garcia, A. M. Evans, and M. Rowland: Application of the axial dispersion model of hepatic drug elimination to the kinetics of diazepam in the isolated perfused rat liver. J. Pharmacokinet. Biopharm. 20, 171-193 (1992).
27. Z. Hussein, A. J. McLachlan, and M. Rowland: Distribution kinetics of salicylic acid in the isolated perfused rat liver assessed using moment analysis and the two-compartment axial dispersion model. Pharm. Res. 11, 1337-1345 (1994).
28. M. Nishimura, K. Yamaoka, H. Yasui, S. Naito, and T. Nakagawa: Local Disposition of a new xanthine oxidase/xanthine dehydrogenase inhibitor, BOF-4272, in rat liver. Biol. Pharm. Bull. 17, 1301-1304 (1994).
29. Y. Yano, K. Yamaoka, and H. Tanaka: A nonlinear least squares program, MULTI(FILT), based on fast inverse Laplace transform for microcomputers. Chem. Pharm. Bull. 37, 1035-1038 (1989).
30. T. Hosono: Numerical inversion of Laplace transform and some applications to wave optics. Radio. Sci. 16, 1015-1019 (1981).
31. 131 by the cyclically perfused rat liver. Ann. N.Y. Acad. Sci. 82, 329-337 (1959).
32. F. B. Freedman and J. A. Johnson: Equilibrium and kinetic properties of the Evans blue-albumin system. Am. J. Physiol. 216, 675-681 (1969).
33. M. Fujita, S. Ito, H. Suhara, H. Ibuki, and Y. Kawashima: Synthesis and calcium antagonistic activities of fecal metabolites of a new calcium antagonist (+)-(R)-3,4-dihydro-2-[5-methoxy-2-[3-[N-methyl-N-[2-[(3,4-methylendioxy) phenoxy]ethyl]amino]propoxy]phenyl]-4-methyl-3-oxo-2H-1,4-benzothiazine (SD-3211) in rats. Yakugaku Zasshi 111, 59-64 (1991).
34. M. Nakaoka, K. Katoh, and H. Hakusui: Biliary metabolites of semotiadil fumarate in the rat. Xenobiotica 25, 847-855 (1995).
35. M. E. Rodriguez, A. Shibukawa, K. Ueda, and T. Nakagawa: Determination of unbound concentration of semotiadil (R-enantiomer) and levose-motiadil (S-enantiomer) in plasma protein solution by use of high-performance frontal analysis. J. Pharm. Biol. Anal. in press.
36. C. A. Goresky: A linear method for determining liver sinusoidal and extravascular volumes. Am. J. Physiol. 204, 626-640 (1963).
37. S. C. Tsao, Y. Sugiyama, Y. Sawada, S. Nagase, T. Iga, and M. Hanano: Effect of albumin on hepatic uptake of warfarin in normal and analbuminemic mutant rats: analysis by multiple indicator dilution method. J. Pharmacokinet. Biopharm. 14, 51-64 (1978).
38. M. S. Roberts, S. Fraser, A. Wagner, and L. McLeod: Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination. 1. Effect of changes in perfusate flow and albumin concentration on sucrose and taurocholate. J. Pharmacokinet. Biopharm. 18, 209-234 (1990).
39. M. Gibaldi and D. Perrier: Apparent volume of distribution. In "Pharmacokinetics," 2nd ed., pp. 199-219. Marcel Dekker, New York, 1982.